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Abstract: The preparation of oligonucleotide conjugates carrying viologen and fluorescein is described. Reaction of the 
appropriate carboxyl derivatives with oligonucleotides carrying aliphatic amino groups gave the desired compounds. A 
simple method for the introduction of the amino group at the 5’-end of the oligonucleotides is reported.  
INTRODUCTION  
 The conjugation of oligonucleotides to different func-
tional molecules is a valuable tool that allows for modulation 
of both therapeutical and biotechnological properties. Such 
conjugate groups confer a variety of important properties, 
these include fluorescent emission to allow sensitive detec-
tion [1, 2], altered hydrophobicity or bioaffinity [3, 4], en-
hanced cellular uptake [5, 6], resistance towards degradation 
[7], novel electrochemical properties [8] and the ability to 
coordinate metal ions [9], to mention just a few. Accord-
ingly, convenient synthetic protocols for the preparation of 
oligonucleotide conjugates are of great interest. 
 The two principle methods for the synthesis of oligonu-
cleotide conjugates involve (1) the introduction of the modi-
fication as an individual phosphoramidite or (2) post-
synthetic modification of oligonucleotide through the cou-
pling of a ligand once the oligomer is fully synthesized. The 
main disadvantage of the first method is the requirement that 
each conjugate molecule must first be prepared as a 
phosphitylated building block. For this reason the second 
approach is considered the more versatile strategy and it 
typically involves the insertion of a masked nucleophilic or 
electrophilic group into the oligonucleotide chain. To date, 
aliphatic amino groups have been extensively used for this 
purpose. Attachment of this group to one end of the oligonu-
cleotide allows for facile reaction with incoming functional 
groups in the form of electrophiles (e.g., activated carboxylic 
groups [10-12], isothiocyanates [13, 14], alkylating agents 
and aldehydes with further reduction by sodium borohydrate 
[15, 16]). 
 In most cases the desired functional molecule is intro-
duced during solid-phase synthesis. However, this is not  
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possible in instances where the desired ligand to be attached 
is incompatible with conditions under which oligonucleotide 
deprotection and cleavage occurs. This is the case for base 
labile compounds (such as the viologen molecule reported in 
this article). These base labile groups necessitate the use of 
appropriately modified linkers that allow for the oligonu-
cleotide synthesis to take place on the support and conjuga-
tion to occur after the cleavage step. 
 We are interested in the preparation of oligonucleotide 
conjugates carrying compounds such as viologens, and fluo-
rescent compounds such as fluorescein. Viologens (1,1-
disubstituted 4,4’-bipyridinium dications) are a well-studied 
class of redox chromophores [17-21]. They have one of the 
lowest redox potentials of any organic molecule [17]. In ad-
dition, they exhibit a large change in the visible extinction 
coefficient following reduction and possess a first reduction 
potential that is essentially pH independent. Due to these 
properties many attempts have been made to incorporate 
these molecules in electrochromic devices [20-22]. Moreover 
these molecules may be used as electron acceptors to meas-
ure electron transport in DNA [22, 23]. To this end, violo-
gens have to be incorporated in synthetic oligonucleotides 
but preliminary studies have shown that these molecules are 
not stable to the ammonia [23-25], reagent that is used for 
the removal of the protecting groups in DNA synthesis. In 
the present report we describe the efficient synthesis of oli-
gonucleotide conjugates by reaction of oligonucleotides car-
rying amino groups with the appropriate carboxyl deriva-
tives. 
 A protected aliphatic amino group can be readily intro-
duced in the 5’ terminus through commercially available 
phosphoramidites, such as the N-monomethoxytrityl (MMT) 
-6-amino-hexyl phosphoramidite [26]. This compound was 
used to obtain the 5’-amino sequences that were conjugated 
to viologen in this study. 
 However previous studies [27] have shown that MMT 
protection does not completely prevent the reactivity of the 
5’-amino group toward N-acetylation (coming from capping 
42    The Open Organic Chemistry Journal, 2008, Volume 2 Alvira et al. 
reagents). This effect was also observed by Zaramella et al. 
[28] during the assembly of a peptide at the 5’-end of the 
target oligonucleotide. N-acetylation of the amino group 
leads to a loss in reactivity and consequently reduces the 
efficiency of oligonucleotide functionalisation. Furthermore, 
the deprotection of MMT occurs under stringent acid condi-
tions and typically involves reaction of the oligonucleotide 
for over one hour in 80 % aqueous acetic acid solution. In 
some cases this does not remove MMT completely [29, 30], 
and can cause depurination. Alternatively, in a reverse of this 
strategy, chloroacetamidohexyl phosphoramidite has been 
used to introduce an electrophillic group in oligonucleotides 
[31]. In this case the reaction of primary amines or mercap-
tans with this chloroacetamido group afforded a variety of 
oligonucleotide conjugates in good yields.  
 In the work presented here we have overcome the chal-
lenges mentioned above by developing a protocol that em-
ploys a 6-bromohexyl phosphoramidite intermediate that 
leads to a 5’-aminohexyl oligonucleotide after ammonia 
cleavage from the support.  
RESULTS AND DISCUSSION 
Synthesis of Oligonucleotides Carrying Viologen 
 The viologen derivative, 1-Ethyl-1’-(5-carboxypentyl)-
4,4-bipyridinium di(hexafluorophosphate), 1 carrying a car-
boxylic group was chosen for reaction with the amino-
oligonucleotides. This compound was prepared according to 
literature procedures [32-34]. 
 The stability of compound 1 to ammonia was checked by 
treating aliquots of compound with concentrated ammonia. 
The rapid decomposition of viologen 1 was observed, even 
at room temperature. The decomposition was revealed by 
HPLC analysis with the initial compound replaced by two 
new products with higher retention times. These two com-
pounds are most probably the olefins from a ?-elimination 
reaction of the N-alkyl quaternary ammonium groups. These 
results are in agreement with previous studies [22, 23] and 
suggest that viologen molecules should be incorporated to 
oligonucleotides after ammonia treatment (Scheme 1). 
 Oligonucleotides A (5’-NH2-TCAGTAGTCAG) and B 
(5’-NH2-TTCAGTAGTCAG) with a primary amino group 
attached to the 5’-end were synthesized using the N-MMT-6-
aminohexyl phosphoramidite [26]. 5’-Amino oligonucleo-
tides were treated with viologen 1 using N-
hydroxysuccinimide and diisopropylcarbodiimide as activat-
ing agents. The resulting products were desalted with a Se-
phadex G-25 column and purified by RP-HPLC (Table 1). 
The HPLC analysis revealed a major peak which was col-
lected. Mass spectrometry confirmed that the desired product 
corresponded to the major peak on the chromatogram (Table 
1). In both cases, the conversion to the desired compound 
was greater than 80%.  
Synthesis of Oligonucleotides Carrying Amino Groups at 
the 5’-end Using the Bromohexyl Phosphoramidite 
 An alternative synthesis of the oligonucleotide carrying 
aminohexyl group was achieved following the steps pre-
sented in Scheme 2. Oligonucleotide sequences C (5’-
CTTCCTCCTCT-3’) and D (5’-GACTCGAT-3’) were syn-
thesized using standard phosphoramidites. The bromohexyl 
linker was incorporated into the 5’ terminus through a phos-
phoramidite that was obtained from 6-bromohexan-1-ol ac-
cording to the protocol described in [35]. 
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Scheme 2. Synthesis of the 5’-aminohexyl oligonucleotides. 
 
 The supports carrying the 5’-Br-oligonucleotide were 
treated with concentrated aqueous ammonia at room tem-
perature, giving the desired 5’-aminohexyl-oligonucleotide 
as the major product (see chromatogram in Fig. 1). The 5’-
bromohexyl oligonucleotide was also observed. Various at-
tempts to enhance the yield of nucleophilic substitution were 
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Scheme 1. Synthesis of oligonucleotide-viologen conjugates. 
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made using longer times and higher temperature but only a 
slight improvement was observed. (Fig. 2). The purified oli-
gonucleotides had the expected mass. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). HPLC profile obtained after treatment of the 5’-Br-
oligonucleotide-support (sequence C) with concentrated aqueous 
ammonia for 3 hours at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). HPLC profile obtained after treatment of the 5’-Br-
oligonucleotide-support (sequence C) with concentrated aqueous 
ammonia for 5 hours at 55ºC. 
 
 To confirm that our purified products contained the 
amino terminal group and that the obtained mass does not 
come from a substitution of bromide with an hydroxyl group 
(in which case the oligomer would be expected to have a 
similar mass) we decided to couple a ligand with a carbox-
ylic group that would lead to an easily detectable conjugate. 
 5(6)-carboxyfluorescein N-hydroxysuccinimide ester 2 
was coupled to the oligonucleotide C as detailed in the 
Experimental Section. Fig. (3) shows the HPLC profile of 
the reaction. The desired fluorescein labelled oligonucleotide 
was obtained as a major product (tR = 11.2 min). The peak 
eluting at 10.2 min corresponds to the coupling of the oli-
gomer with one of the isomers of the fluorescein (as the 
commercial reagent is a mixture of 5- and 6-
carboxyfluorescein isomers). Both products had the expected 
mass. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). HPLC profile obtained after conjugation of the 5’-NH2-
oligonucleotide (sequence C) with the fluorescein derivative 2. 
 
CONCLUSIONS 
 In conclusion, we have demonstrated that viologen modi-
fied oligonucleotides can be prepared by post-synthetic con-
jugation of oligonucleotides carrying amino groups. This is 
relevant as the introduction of these molecules in DNA is of 
interest for studies DNA-mediated electron transfer. We also 
described a straightforward protocol to incorporate an ami-
nohexyl linker at the 5’ terminus of an oligonucleotide that 
allows the attachment of appropriately functionalised ligands 
in solution phase. Finally, the use of a bromohexyl linker as 
an intermediate for the introduction of the nucleophilic 
amino group was shown to overcome the disadvantages pre-
sented by some protected amino modifier phosphoramidites. 
The desired 5’-amino oligonucleotide was easily obtained 
upon addition of ammonia during the cleavage of the product 
from the solid support. We believe that these observations 
present an important contribution to this growing field.  
EXPERIMENTAL SECTION 
Oligonucleotide Synthesis and Purification 
 Oligonucleotide sequences were prepared using solid-
phase methodology and 2-cyanoethyl phosphoramidites as 
monomers. The syntheses were performed on an Applied 
Biosystems Model 3400 DNA synthesizer using 1 μmol 
scale. Oligonucleotides were purified by reversed-phase 
HPLC. HPLC conditions I: a 20 min gradient from 0% B to 
50% B; II; using a 20 min linear gradient from 5 to 35 % of 
B with a flow rate of 3 ml/min. HPLC solutions are as fol-
lows: Solvent A: 5% ACN in 100 mM triethylammonium 
acetate (pH 6.5) and solvent B: 70% ACN in 100 mM trieth-
ylammonium acetate pH 6.5. The column used in conditions 
I was PRP-1, 10 μm, (Hamilton), 250x8 mm. In conditions II 
was a Nucleosil 120C18 (10 μm), 200 x 10 mm. 
Stability of Compound 1 in Ammonia 
 1-mg aliquots of compound 1 were dissolved in concen-
trated ammonia (1 ml). The samples were treated at room 
temperature and 55 ºC. Then samples were concentrated and 
analyzed by HPLC (conditions I). 
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Synthesis of Oligonucleotide Carrying Viologens 
 Oligonucleotides A (5’-NH2-TCAGTAGTCAG) and B 
(5’-NH2-TTCAGTAGTCAG) with a primary amino group 
(N-MMT-6-aminohexanol phosphoramidite) attached to the 
5’-end were synthesized on an automatic DNA synthesizer 
using the standard phosphoramidites. They were deprotected 
with ammonia and desalted with a Sephadex G-25 column 
(NAP-10). Interfering ammonium ions present from the de-
protection steps were removed by passing a solution of the 
oligonucleotide in water through a small column filled with 
Dowex 50 x 2 (sodium form).  
 5’-Amino oligonucleotides (30 O.D. units) were dis-
solved in 0.2 ml of 0.5 M aqueous sodium carbonate buffer 
(pH 9) and a solution of viologen 1 (5 μmols), N-
hydroxysuccinimide (5 μmols) and diisopropylcarbodiimide 
(5 μmols) in 0.15 ml of N,N-dimethylformamide was added. 
The mixtures were incubated at room temperature overnight 
and the solutions were concentrated to dryness. The resulting 
products were first desalted with a Sephadex G-25 column 
(NAP-10) and purified by RP-HPLC (Table 1). The HPLC 
analysis revealed a major peak which was collected. Mass 
spectrometry confirmed that the desired product corre-
sponded to the major peak on the chromatogram (Table 1). 
In both cases, the conversion to the desired compound, esti-
mated by comparison of the areas under the peaks, was 
higher than 80%. Recoveries were 9 OD (30%) for sequence 
A and 15 OD (50%) for sequence B. 
Synthesis of the Phosphoramidite of 6-Bromohexanol 
 6-Bromohexanol was reacted with 2-cyanoethoxy-N,N- 
diisopropylaminochlorophosphine in dry acetonitrile and 
N,N-diisopropylethylamine as described in reference [35]. 
Synthesis of 5’-Amino-Oligonucleotides Using the Phos-
phoramidite of 6-Bromohexanol 
 Sequences C: 5’-CTTCCTCCTCT-3’ and D: 5’-
GACTCGAT-3’ were prepared in an automatic DNA syn-
thesizer. A and C nucleobases were protected with the ben-
zoyl group. G was protected either with the classical isobu-
tyryl group or with the more base-labile dimethylforma-
midine group. The phosphoramidite of 6-bromohexanol was 
coupled in the last cycle (without performing final TCA de-
trytilation step) for the later introduction of the amino group 
at the 5’-end. The resulting 5’-bromohexyl oligonucleotides 
were treated with concentrated aqueous ammonia (Fig. 1). 
The resulting 5’-amino oligonucleotides were purified by 
reverse-phase HPLC (conditions II). The two main peaks 
were collected, desalted with a Sephadex G-25 column and 
analyzed by MALDI-TOF. In all the cases the first eluted 
product corresponds to the desired 5’-aminohexyl 
oligonucleotide (MALDI-MS of oligonucleotide C [M-H
+
]: 
3370.1, expected for C110H152N29O72P11: 3372.8.; MALDI-
Table 1 Oligonucleotide Conjugates Prepared in this Work 
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Sequence
1
 (5’->3’) RT (min)
2 
Mass, Found Mass, Calcd. 
A)NH2-hexyl-TCAGTAGTCAG 
9.0 
 (I) 
3532.7 3532.3 
A)1-CONH-hexyl-
TCAGTAGTCAG 
10.0  
(I) 
3815.8 3814.5 
B)NH2-hexyl-TTCAGTAGTCAG 
9.0  
(I) 
3836.5 3836.5 
B)1-CONH-hexyl-
TTCAGTAGTCAG 
9.8 
 (I) 
4119.9 4118.7 
C)NH2-hexyl-CTTCCTCCTCT 
8.7  
(II) 
3370.1 3372.9 
C)2-CONH-hexyl-CTTCCTCCTCT 11.2 (II) 3732.2 3732.1 
D)NH2-hexyl-GACTCGAT 
8.4  
(II) 
2586.4 2588.5 
1
1: viologen derivative . 2: fluoresceine derivative. 
2HPLC conditions. I: a 20 min gradient from 0% B to 50% B. II: a 20 min gradient from 5% B to 35% B (a more detailed description in experimental section). 
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expected for C110H152N29O72P11: 3372.8.; MALDI-MS of 
oligonucleotide D [M-H
+
]: 2586.4, expected for 
C84H113N31O49P8: 2588.5) while the second one is the non-
reacted 5’-bromohexyl oligonucleotide (MALDI-MS of oli-
gonucleotide C [M-H
+
]: 3435.0, expected for 
C110BrH150N28O72P11: 3436.7; MALDI-MS of oligonucleo-
tide D [M-H
+
]: 2651.3, expected for C84BrH111N30O49P8: 
2652.3). 
Fluorescein Conjugation to Oligonucleotides 
 A solution of the deprotected oligonucleotide C was 
passed through a column filled with Dowex 50 x 2, sodium 
form, to remove the interfering ammonium ions coming 
from the cleavage step. 50 nmol of 5’-amino oligonucleo-
tides (5.5 O.D units) were dissolved in 0.2 ml of 0.5 M 
aqueous sodium carbonate buffer, pH 9, and a solution of 
5(6)-carboxyfluorescein N-hydroxysuccinimide ester (10 
μmol) in 50 μl of dioxane was added. The mixture was incu-
bated at room temperature overnight and subsequently con-
centrated to dryness. The resulting products were first de-
salted with a Sephadex G-25 column and purified by RP-
HPLC. The desired oligonucleotide eluted at 11.2 min as a 
major peak, using the eluting conditions mentioned above. 
MALDI-MS: 3732.2, (expected for C131H163N29O78P11: 
3732.1). 
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